BRIEF-Bluebird Bio Temporarily Suspends Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For SCD
* BLUEBIRD BIO ANNOUNCES TEMPORARY SUSPENSION ON PHASE 1/2 AND PHASE 3 STUDIES OF LENTIGLOBIN GENE THERAPY FOR SICKLE CELL DISEASE (BB1111) Source text for Eikon: Further company coverage: